What to Know Before Firing an Employee features critical information for HRmanagers on important documentation and policies
What to Know Before Firing an Employee features critical information for HRmanagers on important documentation and policies that need to be implemented toprotect your company. Take the 60-minutes to view this Instant Impact seminar tomake sure your company’s process and procedures are up to date, as well as beingable to answer questions from other colleagues at your company on the topic. Theseminar also includes the most up to date documentation and forms to use whenfiring an employee, which are in Microsoft Word and can be customized for yourown use. Upon ordering, we will send you a CD with the seminar on it for viewing on yourcomputer or mobile media device (iPod/iPhone, Blackberry). The CD will includethe PowerPoint presentation, audio narration and jpeg images of the slides (forwatching on your mobile media device) The seminar is led by Celia J. Collins(Member, Johnstone, Adams, Bailey, Gordon & Harris, L.L.C), who has almost 30years experience in labor and employment law, defending companies againstemployee lawsuits as well as regularly training management on termination bestpractices.
Trials Designed to Improve Laser Eye Surgery OutcomesOCEANSIDE, Calif.–(Business Wire)–International Stem Cell Corporation (OTCBB:ISCO), the first company to perfect amethod of creating human “parthenogenetic” stem cells from unfertilized eggs,has received positive early results from animal trials designed to improvephotorefractive keratectomy (PRK), a form of corrective laser eye surgery thatoffers an improved alternative to LASIK. PRK is generally thought to be safer and produce better long-term results thanLASIK, but has not been used as frequently because of patient discomfortfollowing surgery and a longer healing time. By combining ISCO`s human cornealcells with a proprietary surgical device developed by Paul H Chen, M.D., who isconducting the trials, ISCO and Dr. Chen believe that cellular enhanced PRK canreplace LASIK for many of the hundreds of thousands of patients who now useLASIK. The first stage animal trials just completed demonstrated that ISCO`s cornealcells manufactured by ISCO`s subsidiary, Lifeline Cell Technology, encouragedcorneal-defect healing in the animals. The trials are the first step towardgaining Food and Drug Administration (FDA) approval to test the efficacy ofusing ISCO`s cells to improve healing after corneal surgery, and could result inthe first FDA approved use of human cells produced by ISCO. Jeffrey Janus, President of ISCO and CEO of Lifeline, noted that “The cells usedin these trials are derived from donated human tissue processed usingproprietary techniques devised by ISCO`s subsidiary, Lifeline Cell Technology.However, ISCO`s parthenogenic stem cells can also produce human corneal cells.Corneal cells derived from ISCO`s parthenogenetic stem cells may provide aconsistent and reliable source of corneal cells that could eliminate entirelythe need for donated human tissues.” This work is being done in collaboration with Dr Chen, who has developed thecell transfer technology Dr.
Chen is an eye surgeon at North County Laser EyeAssociates, and he is on staff at Scripps Memorial La Jolla and ScrippsEncinitas Hospitals. For more news and information on International Stem Cell Corporation pleasevisit where you can find the CEO’s video, a fact sheeton the company, investor presentations, and more.ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB):International Stem Cell Corporation is a California biotechnology companyfocused on developing therapeutic and research products. ISCO`s technology,Parthenogenesis, results in the creation of pluripotent human stem cell linesfrom unfertilized human eggs. ISCO scientists have created the firstParthenogenetic homozygous stem cell line (phSC-Hhom-4) that can be a source oftherapeutic cells that will minimize immune rejection after transplantation intohundreds of millions of individuals of differing sexes, ages and racial groups.These advancements offer the potential to create the first true “Stem Cell Bank”and address ethical issues by eliminating the need to use or destroy fertilizedembryos. ISCO also produces and markets specialized cells and growth mediaworldwide for therapeutic research through its subsidiary Lifeline CellTechnology. For more information, visit the ISCO website at:. To subscribe to receive ongoing corporate communications please click on thefollowing link: http:// FORWARD-LOOKING STATEMENTS:Statements pertaining to anticipated future financial and/or operating results,future growth in research, technology, clinical development and potential jointventure and other opportunities for the company and its subsidiary, along withother statements about the future expectations, beliefs, goals, plans, orprospects expressed by management constitute forward-looking statements.
Anystatements that are not historical fact (including, but not limited tostatements that contain words such as “will,” “believes,” “plans,”"anticipates,” “expects,” “estimates”) should also be considered to beforward-looking statements. Forward-looking statements involve risks anduncertainties, including, without limitation, risks inherent in the developmentand/or commercialization of potential products, uncertainty in the results ofclinical trials or regulatory approvals, need and ability to obtain futurecapital, application of capital resources among competing uses, and maintenanceof intellectual property rights. Actual results may differ materially from theresults anticipated in these forward-looking statements and as such should beevaluated together with the many uncertainties that affect the company’sbusiness, particularly those mentioned in the cautionary statements found in thecompany’s Securities and Exchange Commission filings. The company disclaims anyintent or obligation to update these forward-looking statements.Key Words: Stem Cells, Biotechnology, Parthenogenesis International Stem Cell CorporationKenneth C. Aldrich, Chairman, orJeffrey Janus, orThe Investor Relations Group212-825-3210Investor Relations:Adam S. orMedia Relations:Laura Copyright Business Wire 2009. Dorado and Ness partner to deploy Dorado`s enterprise lending solutions at top10 financial services firmSAN MATEO, Calif.